Stepping forward in antibody-drug conjugate development
Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …
[HTML][HTML] Advances and limitations of antibody drug conjugates for cancer
CM Mckertish, V Kayser - Biomedicines, 2021 - mdpi.com
The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …
[HTML][HTML] Antibody-drug conjugates in lung cancer: dawn of a new era?
N Coleman, TA Yap, JV Heymach… - npj Precision …, 2023 - nature.com
Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …
[HTML][HTML] Antibody–drug conjugates: Recent advances in payloads
Z Wang, H Li, L Gou, W Li, Y Wang - Acta Pharmaceutica Sinica B, 2023 - Elsevier
Abstract Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal
antibodies with precise targeting and payloads with efficient killing, show great clinical …
antibodies with precise targeting and payloads with efficient killing, show great clinical …
[HTML][HTML] Marine anticancer agents: An overview with a particular focus on their chemical classes
M Barreca, V Spanò, A Montalbano, M Cueto… - Marine drugs, 2020 - mdpi.com
The marine environment is a rich source of biologically active molecules for the treatment of
human diseases, especially cancer. The adaptation to unique environmental conditions led …
human diseases, especially cancer. The adaptation to unique environmental conditions led …
[HTML][HTML] Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency
D Su, D Zhang - Frontiers in pharmacology, 2021 - frontiersin.org
The development of antibody-drug conjugates (ADCs) has significantly been advanced in
the past decade given the improvement of payloads, linkers and conjugation methods. In …
the past decade given the improvement of payloads, linkers and conjugation methods. In …
[HTML][HTML] The use of antibody-antibiotic conjugates to fight bacterial infections
The emergence of antimicrobial resistance (AMR) is rapidly increasing and it is one of the
significant twenty-first century's healthcare challenges. Unfortunately, the development of …
significant twenty-first century's healthcare challenges. Unfortunately, the development of …
[HTML][HTML] New insights into the anticancer therapeutic potential of maytansine and its derivatives
Maytansine is a pharmacologically active 19-membered ansamacrolide derived from
various medicinal plants and microorganisms. Among the most studied pharmacological …
various medicinal plants and microorganisms. Among the most studied pharmacological …
Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review
A Beishenaliev, YL Loke, SJ Goh, HN Geo… - Journal of Controlled …, 2023 - Elsevier
Monospecific antibodies have been utilised increasingly for anti-cancer drug targeting owing
to their ability to minimise off-target toxicity by binding specifically to a tumour epitope, hence …
to their ability to minimise off-target toxicity by binding specifically to a tumour epitope, hence …
Trial watch: intratumoral immunotherapy
While chemotherapy and radiotherapy remain the first-line approaches for the management
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …